”Let stem cells repair broken hearts” is the cry of scientists recently published in Nature, the world’s leading scientific journal. It is a clarion call and a vow, a hope for humanity and an expectation for heart patients. Every year, 17 million people in the world die from cardiovascular diseases, of which deaths caused by acute myocardial infarction and chronic cardiac insufficiency account for more than 50% of cardiovascular mortality. In recent years, the early mortality rate of acute myocardial infarction has decreased significantly, despite the continuous improvement of drug therapy, interventional techniques and surgical procedures. However, evidence-based medical studies have shown that even among patients with myocardial infarction successfully treated with revascularization, more than 30% of patients still experience ventricular remodeling with wall thinning and chamber enlargement after myocardial infarction and develop chronic ischemic heart failure (CIHF), because early revascularization can only save the hibernating ischemic myocardium, while the already necrotic myocardium will definitely be replaced by fibrous connective tissue, forming Scarring, which eventually leads to ischemic cardiomyopathy, is currently the leading cause of death from coronary heart disease. Because a single revascularization cannot completely limit the reversal of the pathological process of ventricular remodeling, revascularization must be accompanied by myocardial repair, just like planting a crop, with water channels to irrigate the ground, but also to sow the seeds in order to harvest the fruits. The treatment of myocardial infarction and chronic ischemic heart failure in coronary artery disease is like the above-mentioned crop planting, after opening the occluded blood vessels, new cells should be sown into the necrotic myocardium, which have the ability of self-renewal and differentiation to replace the necrotic myocardial scars, so that the ventricular wall does not become thinner and the heart contraction is stronger, and the stem cells also secrete a variety of important biological factors to promote the regeneration of the heart vessels and truly The purpose of repairing the heart muscle is achieved. This is what scientists around the world call the cutting edge of contemporary biomedical development, stem cell myocardial repair. This is a milestone breakthrough in the history of treatment for coronary heart disease myocardial infarction and chronic ischemic heart failure. The core of stem cell therapy for coronary heart disease is seed cells, what kind of seed cells are best? It is the focus of world research and debate, and has been the focus of our research for a long time. Embryonic stem cells: there are ethical and moral and immune rejection problems cannot be applied to clinical use yet. At present, adult stem cells are mostly used for stem cell transplantation, among which more research applications are bone marrow single nucleus cells, bone marrow mesenchymal stem cells, skeletal muscle stem cells, CD133+, side group cells, endothelial progenitor cells, umbilical cord blood stem cells, etc. Currently, the world’s most promising stem cells are MSCs, which have good potential for self-renewal and differentiation, but are commonly used in autologous stem cells, such as CD133+, which have good regenerative function but can cause restenosis in coronary stents. The most promising is MSCs, which have good self-renewal and differentiation potential. However, the autologous MSCs are derived from patients’ own bone marrow, and the number of MSCs in bone marrow of patients with coronary artery disease, especially the elderly, is very small, and their proliferation ability is very poor, so they need long-term culture in vitro. In response to this problem, the Heart Center of the Naval General Hospital has conducted in-depth research for several years, and has isolated and purified MSCs (UW-MSCs) from a special tissue of the umbilical cord of infants, which are significantly better than autologous MSCs in terms of differentiation and proliferation, biological effects, and phenotypic and immunological identification according to the International Society of Cellular (ISCT). With the consent of the hospital ethics committee, we have transplanted UW-MSCs into several patients with end-stage coronary artery disease, even those with persistent angina and heart failure after medical stenting and surgical bypass, and significantly reduced angina attacks and improved left ventricular ejection fraction. After the first domestic case of transcoronary autologous bone marrow single nucleus cell transplantation for acute myocardial infarction in 2002, the Cardiovascular Medicine Department of the Naval General Hospital has progressed from the application of autologous bone marrow single nucleus cells, bone marrow mesenchymal stem cells, and the latest more primitive mesenchymal stem cells extracted from fetal umbilical cord Huatong gum in the past 8 years, and has treated a large number of patients with coronary heart disease from the first to the second generation of stem cells. At present, with the encouragement of “innovation for the people, benefit for the people” given by the patients, the Heart Center of the Naval General Hospital will bring good news to more patients suffering from coronary heart disease.